Redwire Lands $25M NASA Contract for Biotech Facilities and On-Orbit Services

Redwire, a NYSE-listed company, has been awarded a $25M single award IDIQ contract by NASA for a five-year period. The contract will cover biotechnology facilities, on-orbit operations support, mission integration, and related services.

Jacksonville, Fla.--Redwire Corporation (NYSE: RDW), a leading provider of space and defense technology solutions, has been awarded a NASA single award, indefinite-delivery/indefinite-quantity (IDIQ) contract with a $25 million ceiling for a five-year period. This contract will cover a wide range of services, including biotechnology facilities, on-orbit operations support, mission integration, and related services for NASA's International Space Station (ISS) operations.

Under this contract, Redwire has already been issued a $2.5 million task order from NASA’s In Space Production Applications (InSPA) program to support additional drug development investigations on the ISS using its PIL-BOX technology. Redwire will provide turnkey services to manage, integrate, and facilitate experiments and support on-orbit operations for NASA-funded research investigations aboard the ISS. The company's capabilities are intended to support a diverse range of life and materials sciences research investigations that NASA processes annually.

John Vellinger, President of Redwire In-Space Industries, stated, "Redwire’s biotechnology facilities have been an integral part of NASA’s ISS research strategy, supporting an increased throughput of critical scientific research and expanding on-orbit capabilities to accommodate cutting-edge science in drug development, cancer research, and tissue engineering. As the sole recipient for this IDIQ contract, Redwire is grateful for NASA’s continued trust in our proven biotechnology capabilities and experience, and we are committed to enabling new discoveries for NASA and the ISS science community."

Redwire is a global leader in microgravity research and development technologies, having flown hundreds of experiments on both the Space Shuttle and the ISS. The company's microgravity technology enables space biotechnology and pharmaceutical development, helping companies unlock new insights for potential therapeutics and paving the way for microgravity research on future commercial space stations. Notable research partners include Bristol Myers Squibb, Eli Lilly and Company, and Butler University. Recently, Redwire formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit to create new and reformulated pharmaceuticals.

Redwire Corporation (NYSE:RDW) is an integrated space and defense tech company focused on advanced technologies. With approximately 1,300 employees located throughout the United States and Europe, the company is committed to delivering innovative space and airborne platforms transforming the future of multi-domain operations.

References:
[1] https://finance.yahoo.com/news/redwire-awarded-25-million-single-113000223.html
[2] https://www.nasdaq.com/press-release/redwire-awarded-25-million-single-award-idiq-contract-nasa-provide-biotechnology-and
[3] https://www.stocktitan.net/news/RDW/redwire-awarded-25-million-single-award-idiq-contract-by-nasa-to-vl0han4bnvlt.html